Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of FLAG-Ida With PVEK for Newly Diagnosed Adverse-Risk AML
NCT06034470Phase 1Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pivekimab sunirine in acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), myelodysplastic syndrome (MDS) and 2 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of dose-limiting toxicities at 42 days. Started Dec 2023; status: active, not recruiting.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06034470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034470.